Chief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)
John Boniface, Chief Scientific Officer of Sera Prognostics Inc (NASDAQ:SERA), has sold 22,163 shares of the company on March 25, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $9.1 per share, resulting in a total value of $201,683.30.
Sera Prognostics Inc is a company focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients. The company's tests are designed to predict the risk of preterm birth, preeclampsia, and other pregnancy complications, enabling more informed clinical decisions.
Over the past year, the insider, John Boniface, has sold a total of 55,930 shares of Sera Prognostics Inc and has not made any purchases of the stock. The recent sale on March 25 represents a significant portion of these transactions.
The insider transaction history for Sera Prognostics Inc shows a pattern of insider selling activity. In the past year, there have been 18 insider sells and no insider buys. This trend can be visualized in the following insider trend image:
On the day of the insider's recent sale, shares of Sera Prognostics Inc were trading at $9.1, giving the company a market capitalization of $308.044 million.
For more information and updates on insider trading activity at Sera Prognostics Inc (NASDAQ:SERA), investors and stakeholders are encouraged to follow the company's filings and disclosures with the SEC.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
